N1Natalia V. Buchinskaia 1

Natalia V. Buchinskaia 1

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia V. Buchinskaia 1 has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Epidemiological Characteristics of Patients with Mucopolysaccharidosis Type II (Hunter Syndrome) According to Data from the Russian Registry

    by Natalia V. Buchinskaia, Lidia V. Liazina, Anastasia O. Vechkasova, Natalia V. Zhurkova, Nato D. Vashakmadze, Aleksandr M. Nikonov, Vera I. Kurilova, Yulia V. Maximova, Khasyania F. Aksyanova, Elena G. Bakulina, et al.

    Background . The study was conducted based on data from the Russian registry of patients with mucopolysaccharidosis (MPS) type II. There are no similar studies based on analysis of data from the national MPS registry in Russian Federation . Objective . The aim of the study is to conduct a comprehensive analysis of MPS type II epidemiology and phenotypic features in Russian patients using data from the national registry, as well as to compare the obtained results with corresponding data from international registries. Methods. The retrospective, cross-sectional observational study included data from 177 patients with confirmed diagnosis of MPS type II. Data on medical history, clinical, laboratory, and instrumental examination methods, as well as data on enzyme replacement therapy (ERT) over the period from 2008 to March 2026 was analyzed. Results . The prevalence of MPS type II in Russian Federation was 0.1 per 100,000 population, and 0.54 per 100,000 live births (approximately 1 in 185,000 live births). The geographical distribution of patients was uneven. The median age of first symptoms was 1.0 (0; 2.0) years, the range — from the first months of life to 23 years, and the median age of established diagnosis was 3.0 (2.0; 6.0) years, the range — from 0.1 to 38.9 years. The major symptoms of MPS type II in children at the time of diagnosis included musculoskeletal disorders (99.1%), Hurler phenotype 96.4%, short neck was detected in 88.8%, hepatomegaly (based on physical examination findings) in 91.9% of patients, according to abdominal ultrasound data in 87.7% patients, umbilical and inguinal hernias in 82.1% of patients, cardiovascular damage — in 80.3%, chest deformity — 80.3%, contractures of the hand joints (74.5%), and ENT manifestations (62.4%). 151 (85.3%) patients were alive at the time of data collection. ERT was administered to 140 out of 160 (87.5%) patients with MPS type II. Frequent variants in the IDS gene typical for the Russian population were revealed: recombination IDS/ps IDS2 ex3/int7, variants p.Gly374=, p.Arg468Gln, p.Ala85Thr, p.Pro86Leu and p.Arg443Ter. Conclusion. The prevalence of MPS type II in Russian Federation is comparable to data from international registries. The registry-based approach enables the dynamic analysis of the disease’s clinical signs, treatment efficacy evaluation, and planning of healthcare resources. Further expansion of clinical part of the registry, regular data updates, and integration with international registry platforms are crucial for in-depth research and for obtaining more comprehensive data on patients with orphan diseases.

  • Open Access

    Early Recognition of Patients with Neuronopathic Forms of Mucopolysaccharidosis Type II in Clinical Practice

    by Natalia V. Buchinskaia, Ekaterina Yu. Zakharova, Anastasia O. Vechkasova, Irina A. Chikova, Nato D. Vashakmadze, Leyla S. Namazova-Baranova, Dmitry O. Ivanov, Sergei I. Kutsev, Mikhail M. Kostik

    Background: Mucopolysaccharidosis type II (MPS II) is a progressive, rare, X-linked inherited disease with multi-organ involvement and a restricted life expectancy. The disease has two main forms: neuronopathic (severe) and non-neuronopathic (attenuated). Aim: To compare the two main forms of MPS II to identify signs for early recognition of severe disease forms in daily practice. Methods: In this retrospective cohort study, clinical and laboratory data, as well as enzyme replacement therapy data, for approximately 162 patients were extracted and analyzed from the Russian MPS II registry. Patients with insufficient clinical information (23 patients) and children under 5 years of age (15 patients) were excluded. We compared patients with MPS II neuronopathic (n = 82, 66.1%) and non-neuronopathic forms (n = 42, 33.9%) based on the presence of cognitive deficits after age 6 years and on remaining committed to the phenotype throughout follow-up. Results: The patients with both forms had the following symptoms with similar frequency: Hurler phenotype, hernias, hepatosplenomegaly, short neck, orthopedic problems: spinal pathology (curvature), chest deformity, joint stiffness, deformity of the hand, hand contractures, wrist joint deformity and contractures, elbow joint deformity and contractures, shoulder and knee deformity and contractures, hip contractures, cardiomyopathy, obstructive respiratory tract diseases, noisy breathing, hearing loss, carpal tunnel syndrome. Highly specific symptoms (frequency of occurrence above 80%) for the diagnosis of the neuronopathic form of MPS II were: delayed intellectual disability at the age of 1–3 years, epilepsy, and the presence of gross rearrangements in the IDS gene. Highly sensitive symptoms (above 80%) were: psychomotor development delay of up to 1 year of age and delayed intellectual disability at the ages of 1–3 years, heart damage, and myxomatous degeneration of the valves (79.5%). A symptom with high sensitivity and specificity is delayed mental and speech development between the ages of one and three, with respective sensitivities and specificities of 94.8 and 86.5. Conclusions: Identifying symptoms characteristic of neuronopathic forms of MPS is important not only for determining the clinical form of the disease but also for developing various approaches to treating such patients. Early diagnosis of severe forms of MPS II will make it possible to use currently approved methods of intraventricular enzyme replacement therapy, or primarily use of ERT capable of crossing the brain-blood barrier which could improve the prognosis for such patients. Symptoms that predict the risk of developing the neuronopathic form can be used in clinical practice.

  • Diagnostic Quest of a Patient with a Mild Form of Mucopolysaccharidosis, Type I (Scheie Syndrome): Case Study

    by Natalya V. Buchinskaya, Anastasia O. Vechkasova, Ekaterina Е. Shipovskova, Nato D. Vashakmadze, Mikhail M. Kostik

    Background. Diagnosis of mild forms of mucopolysaccharidosis (MPS) causes significant difficulties, and its untimely recognition delays pathogenetic therapy initiation. Case description . Girl Ya., was consulted by neurologist at the age of 6 months due to delayed motor development. Umbilical hernia was diagnosed at the age of 1 year, appearance of fine motor disorders, adenoid hypertrophy and hearing impairment were noted at the age of 3 years, elbow and knee stiffness, gait disturbance, fatigue, exertional dyspnea, and corneal opacity — at 4 years, myelopathy of cervical spinal cord with flail hands paraparesis, external hydrocephalus, flexion elbow contractures, varus feet deformity, and bilateral tubotitis were diagnosed in the hospital at the age of 5. She was examined by a geneticist for а first at the age of 8, disease from the MPS group was suspected. Decreasein arylsulfatase B activity (1.8 nM/mg/h) (reference values 42.8–129.8 nM/mg/h) and dermatan sulfate excretion were revealed, thus, MPS, type VI was suspected. Full sequencing of the ARSB gene was performed, no pathogenic or probably pathogenic variants were revealed. Arylsulfatase activity was within the reference values during the next analysis, however dramatic decrease in a-L-iduronidase activity was detected — up to 0.001 μM/L/h (reference values 1–25 μM/L/h). Pathogenic variant c.208C> T (p.Gln70*) was revealed in exon 2 of the IDUA gene, as well as variant of unknown clinical value c.1505G> C (p.Arg502Pro) in exon 10, both in a heterozygous state. The patient was diagnosed with mucopolysaccharidosis, type I (Scheie syndrome). Pathogenetic (enzyme replacement) therapy was initiated, its results were followed-up until the age of 17 years old. Conclusion . Early diagnosis of MPS is crucial for timely pathogenetic treatment initiation, as it can significantly improve the prognosis for mild forms of the disease.

  • Open Access

    Scheie Syndrome Diagnosis in Early Childhood: Case Study

    by Nataliya V. Buchinskaya, Anastasia O. Vechkasova, Ekaterina D. Ganina, Ekaterina Е. Shipovskova, Victoriya A. Lapina, Yana A. Ananyeva, Nataliya V. Zhurkova, Nato D. Vashakmadze, Vladimir M. Kenis, Mikhail M. Kostik

    Background. Diagnosis of the mild form of mucopolysaccharidosis type I (MPS I) — Scheie syndrome — can be problematic due to its non-specific manifestations. However, its early detection is crucial for the timely therapy initiation and for improving patients’ quality of life. Case presentation. Boy P. with unremarkable medical history was observed by neurologist due to muscle hypotension from thefirst months of life. The child had decrease in body weight after implementation of supplemental feeding at the age of 6 months, thus, they have administered to pediatrician. Further examination has been recommended. He was re-consulted by neurologist due to muscle hypotension, delayed motor development was noted. Enzyme diagnosis (dry blood spots) was performed according to geneticist recommendation: significant decrease in alpha-L-iduronidase activity was detected — up to 0.02 μmol/L (reference values 1.0–25 μmol/L). One-dimensional electrophoresis of urine glycosaminoglycans has revealed dermatan sulfate, heparan sulfate, chondroitin sulfate excretion. The analysis of exon 2 in the IDUA gene was performed via direct automatic sequencing. Previously described pathogenic variant c.208C>T (p.Gln70Term) inherited from child’s father and previously described variant c.250G>A (p.Gly84Ser) inherited from the mother were revealed in compound-heterozygous state. Ultrasound examination of the abdominal organs has revealed gallbladder deformation, echocardiography — paravalvular regurgitation on the mitral and tricuspid valves. Minimal changes in hands, hip joints, and cervical spine were noted according to imaging studies. Conclusion. Early diagnosis of MPS I is crucial for timely therapy initiation and patients’ quality of life improvement. In this regard and considering wide range of symptoms in mild forms of MPS I, it is necessary to increase the awareness of medical workers about this pathology. Moreover, we should introduce a multi-level approach to diagnosis, including both clinical and laboratory research methods.


  • Open Access

    Ранняя диагностика врожденных эндокринопатий с внедрением расширенного неонатального скрининга

    by А.в. Ершова, М.е. Туркунова, А.ю. Лобенская, В.в. Малых, А.о. Вечкасова, Н.в. Бучинская, Н.а. Гладкова, Ю.с. Кошевая, А.а. Андраева, Л.м. Рыбкина, et al.

    Актуальность. Неонатальный скрининг (НС) на врожденный гипотиреоз (ВГ) и врожденную дисфункцию коры надпочечников (ВДКН) является ключевым звеном в системе оказания медицинской помощи детям с данными эндокринными заболеваниями, который используется во всем мире на протяжении нескольких десятилетий. В России скрининг на ВГ проводится с 1993 года, а с 2006 года — ВДКН. С введением расширения перечня заболеваний, исследуемых в неонатальный период, с 2023 года изменены и условия его проведения. Так, определены более ранние сроки определения гормональных показателей в качестве критериев диагностики ВГ и ВДКН: на 1–2-е сутки жизни для доношенных детей (вместо 3–5 суток) и 7-е сутки для недоношенных детей (вместо 7–14-х суток жизни). Физиологические особенности динамических гормональных изменений новорожденного ребенка в первую неделю жизни могут привести к увеличению ложноположительных результатов и росту ошибочных диагнозов ВГ и ВДКН. Цель. Проведение сравнительного анализа результатов неонатального скрининга на ВГ и ВДКН в 2022 и в 2023 годах у новорожденных детей, рожденных в Санкт-Петербурге, при изменении условий взятия крови для определения тиреотропного гормона (ТТГ) при ВГ и 17-гидроксипрогестерона (17ОНПГ) при ВДКН соответственно. Материалы и методы. Проведено ретроспективное одноцентровое сравнительное исследование. Были проанализированы данные о повышенных результатах в первом сухом пятне при проведении неонатального скрининга на ВГ и ВДКН в 2022 и 2023 годах. Для проведения углубленного статистического анализа сформированы группы новорожденных, родившихся при сроке гестации более 37 полных недель, и весом более 2500 г. Выполнен сравнительный статистический анализ уровня ТТГ и 17ОНПГ в зависимости от срока взятия сухих пятен крови для проведения неонатального скрининга. Результаты. В 2022 году обследовано 51 203 новорожденных, повышение 17ОНПГ в первом сухом пятне зарегистрировано у 213 (0,4%), в 2023 году обследовано 51 306 новорожденных, отклонения от нормы выявлены у 1373 (2,7%) детей. При сравнении уровня 17ОНПГ в первом сухом пятне в 2022 и 2023 годах установлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятен крови для обследования. У доношенных новорожденных с массой более 2500 г в 2022 году (n=44 875) медиана уровня 17ОНПГ 7,5 [5,6–9,9] нмоль/л, в 2023 году (n=46360) — 12,4 [9,7–16,0], (р <0,001). При сравнении уровня ТТГ в первом сухом пятне в 2022 и 2023 годах выявлены статистически значимые различия — медиана показателя выше при более раннем взятии сухих пятнен крови для обследования. У доношенных новорожденных массой более 2500 г в 2022 году (n=44 870) медиана уровня ТТГ 2,0 [1,4–2,7] мкМЕ/мл, в 2023 году (n=46 363) — 3,9 [2,9–5,3], (р <0,001). Выводы. Рост числа ложноположительных результатов не сопровождается значимым увеличением ожидаемого количества пациентов с подтвержденным диагнозом. Увеличение количества ложноположительных результатов при исследовании 1-го сухого пятна может быть связано с более ранним взятием крови у новорожденного. Это усложняет лабораторную диагностику, постановку верного диагноза и определяет необходимость возможной коррекции референсных интервалов как 17ОНПГ, так и ТТГ. Background. Neonatal screening (NS) for congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH) plays a pivotal role in the early medical care of children with these endocrine disorders and has been utilized globally for several decades. In Russia, screening...


  • Lysosomal storage diseases. Glycoproteinoses — oligosaccharidoses

    by Victoria N. Gorbunova, Natalia V. Buchinskaia, Anastasia O. Vechkasova, Бучинская Наталья Валерьевна

    The epidemiology, clinical, biochemical and molecular genetic characteristics of oligosaccharidoses are presented — a group of rare autosomal recessive lysosomal diseases, includes sialidosis, mannosidosis, fucosidosis, aspartylglucosaminuria and α-N-acetylgalactosaminidase deficiency. All these diseases are caused by impaired catabolism of glycoproteins and excessive accumulation of various types of oligosaccharides in lysosomes. Clinically, they are characterized by progressive neuropsychiatric disorders combined with a mild gurler-like phenotype. Two genetically heterogeneous variants of alpha- and beta-mannosidosis are caused by mutations in the MAN2B1 and MANBA genes, respectively, and hereditary deficiency of two related α- and β-mannosidases. The cause of the development of fucosidosis is inactivating mutations in the FUCA1 gene, leading to deficiency of lysosomal α-L-fucosidase and accumulation of fucoglycoproteins and fucoglycolipids. The pathogenesis of aspartylglucosaminuria is associated with impaired catabolism of aspartylglucosamine and its accumulation in the lysosomes of liver, spleen, thyroid, kidney and brain cells. The cause of α-N-acetylgalactosaminidase deficiency is mutations in the NAGA gene and the accumulation of uncleaved glycoconjugants in lysosomes. A description of existing experimental models is presented and their role in studying the pathogenesis of these severe lysosomal diseases and the development of various therapeutic approaches is discussed. The most successful treatment for alpha-mannosidosis has been enzyme replacement therapy using a recombinant enzyme — velmanase alfa, which has already passed phase III clinical trials and is used in clinical practice. Pathogenetic treatments for the other oligosaccharidoses discussed here have not been described, although preclinical trials have shown promise for hematopoietic stem cell transplantation and gene therapy for the treatment of β-mannosidosis and aspartyl glucosaminuria, respectively.

  • Open Access

    Differential Diagnosis of Hurler and Hurler–Scheie Syndromes: Clinical Case

    by Nataliya V. Buchinskaya, Anastasiya O. Vechkasova, Ekaterina E. Shishunova, Yuliya S. Kravtsova, Nato D. Vashakmadze, Nataliya V. Zhurkova, Mikhail M. Kostik, Ю. С. Кравцова

    Background. Mucopolysaccharidosis type I (MPS I) is a disease known for over 100 years. Implementation of new management approaches for MPS I requires from doctor to clearly differentiate subtypes of this disease for the effective and rational use of treatment methods. Clinical case description. Girl B. with early MPS I onset during the neonatal period. Symptoms of musculoskeletal system damage were the following: feet adduction and hip joints dysplasia. Further follow-up at the age of 6 months has shown linear growth retardation, umbilical hernia, and exudative otitis. Psychomotor development up to 1 year of age was delayed. Coarse facial features by the age 1.5 years along with orthopedic problems, exudative otitis, and umbilical hernia led to mucopolysaccharidosis diagnosis. The diagnosis of mucopolysaccharidosis type I was established according to clinical findings, enzyme diagnostics (significant decrease in lysosomal enzyme alpha-L-iduronidase activity — 0.26 μmol/l/h; reference values from 1.96), and molecular genetic testing (pathogenic variant c.208C>T (Gln70Ter) in exon 2 and nucleotide variant of unknown clinical value c.1524G>C (p.Glu508Asp) in exon 10 of IDUA gene in compound heterozygous state). Echocardiography has revealed structural changes in the mitral valve and minimal aortic insufficiency. Abdominal ultrasound has revealed signs of hepatomegaly, hydrocalycosis, right-side pyelectasia, kidneys’ sizes lesser than the age norms. Abdominal magnetic resonance imaging has shown simple kidney cysts. Conclusion. The major feature of this clinical case is the complexity of differential diagnosis between the severe form of MPS I, Hurler syndrome, and milder form, Hurler–Scheie syndrome. Molecular genetic testing has revealed the presence of the frequent pathogenic variant c.208C>T (Gln70Ter) in the IDUA gene associated with severe disease course and nucleotide variant c.1524G>C (p.Glu508Asp) with undefined clinical significance, thus, additional examination is necessary. Functional analysis of the novel variant is required to establish its role in protein function. It will help more precisely determine the disease form and predict its severity. Combination of MPS I and polycystic kidney disease in the proband is unique case.


  • Open Access

    Exploring the Phenotypic Heterogeneity and Bioenergetic Profile of the m.13513G>A mtDNA Substitution: A Heteroplasmy Perspective

    by Tatiana Krylova, Yulia Itkis, Polina Tsygankova, Denis Chistol, Konstantin Lyamzaev, Vyacheslav Tabakov, Svetlana Mikhaylova, Natalia Nikitina, Galina Rudenskaya, Aysylu Murtazina, et al.

    The m.13513G>A (p.Asp393Asn) substitution in the MT-ND5 (Mitochondrially Encoded NADH/Ubiquinone Oxidoreductase Core Subunit 5) gene is a common pathogenic variant associated with primary mitochondrial disorders. It frequently causes Leigh syndrome and mitochondrial encephalomyopathy with lactate acidosis and stroke-like episodes (MELAS). In this study, we present clinical data, heteroplasmy levels in various tissues (blood, urine, and skin fibroblasts), and bioenergetic characteristics from a cohort of 20 unrelated patients carrying the m.13513G>A mutation, classified according to the following phenotypes: Leigh syndrome (n = 12), MELAS (n = 2), and Leber’s hereditary optic neuropathy (LHON, n = 6). We observed a significant correlation between high respiratory ratios and heteroplasmy levels in fibroblast cell lines of the patients. Furthermore, fibroblast cell lines with heteroplasmy levels exceeding 55% exhibited markedly reduced mitochondrial membrane potential. These findings contribute to a better understanding of the clinical and bioenergetic profiles of patients with m.13513G>A-variant-related phenotypes across different heteroplasmy levels, based on data from a single genetic center. Our data suggest that even a slight shift in heteroplasmy can improve cellular function and, consequently, the patients’ phenotype, providing a solid foundation for the development of future gene therapies for mtDNA diseases.


  • Open Access

    Epidemiology of Mucopolysaccharidosis Type II According to the Register of the Russian Federation

    by Natalia V. Buchinskaia 1, Ekaterina Yu. Zakharova, Yulia S. Koshevaya, Anastasia O. Vechkasova, Rostislav K. Skitchenko, Aleksandr M. Nikonov, Vera I. Kurilova, Yulia V. Maximova, Khasyanya F. Aksyanova, Elena G. Bakulina, et al.

    Objective: The study aimed to evaluate the epidemiological, clinical, and molecular data of mucopolysaccharidosis type II (MPS II) patients and their outcomes using the national registry of patients in the Russian Federation (RF). Materials and Methods: In the retrospective cohort study, the authors included data from the Russian national registry of MPS II. Results: The prevalence of MPS II in RF is 0.62 per 100 000 live births or 0.09 per 100 000 population with the majority of patients in the Central (n = 36) and the Volga Federal District (n = 35). Males were 157 (99.4%), positive MPS II family history had 47 (29.7%) patients. The median age of the first symptoms was 1.8 (0.8-2.6) years, ranging from 0.1 to 19 years, and the age of diagnosis was 4.0 (2.5; 5.9) years, ranging from 0.1 to 38.9 years. A genetic study was available for the analysis in 116 (73.4%) patients. Single nucleotide variants in the IDS gene were found in 98/116 (84.5%) patients, and 18 further patients (15.5%) had gross rearrangements. About 59/98 (60.2%) patients had missense, 15/98 (15.3%) had frame-shift variants, 12/98 (12.2%) had splice site, and 11/98 (11.2%) had nonsense variants. One (1.0%) patient out of 98 patients had a small deletion. Pathogenic, likely pathogenic variants, and variants with uncertain significance were found in 54 (55.1%), 36 (36.7%), and 8 (8.2%) patients, respectively. About 138 (87.3%) patients received enzyme replacement therapy. Conclusion: The prevalence of MPS II in the RF is higher than that in some European countries and closer to the Asian population. The registry is a convenient tool for disease epidemiology and monitoring. Cite this article as: Buchinskaia NV, Zakharova EY, Koshevaya YS, et al. Epidemiology of mucopolysaccharidosis type II according to the national register of the Russian Federation. Turk Arch Pediatr. 2025;60(1):41-47.


  • Lysosomal storage diseases. Mucolipidosis

    by Viktoria N. Gorbunova, Natalia V. Buchinskaia, Anastasia O. Vechkasova, Бучинская Наталья Валерьевна

    The epidemiology, clinical, biochemical and molecular genetic characteristics of mucolipidoses — autosomal recessive lysosomal storage diseases that combine the clinical manifestations of mucopolysaccharidoses and sphingolipidoses — are presented. In accordance with the modern classification, types I, II and III mucolipidoses are classified as glycoproteinoses, and type IV mucolipidoses are classified as gangliosidoses. Mucolipidoses type I, or sialidosis, is caused by the presence of inactivating mutations in the α-neuraminidase gene NEU1, and a related disease is galactosialidosis, accompanied by secondary deficiency of α-neuraminidase and β-galactosidase in the CTSA gene of the protective protein cathepsin A. Both diseases are characterized by early progressive delay in psychomotor development, muscle myoclonus, severe ophthalmopathy and early death of patients. The pathogenesis of diseases is associated with excessive accumulation of sialocontaining glycoproteins and oligosaccharides in lysosomes. Hereditary deficiency of N-acetylglucosaminyl-1-phosphotransferase, necessary for the addition of mannose-6-phosphate to the oligosaccharides of lysosomal enzymes, underlies the development of two allelic diseases caused by mutations in the GNPTAB gene mucolipidoses type II, or “I-cell” disease and mucolipidoses type III, alpha/beta or pseudopolydystrophy of Hurler. Mutations in the GNPTG gene, which encodes the gamma subunit of this enzyme, are responsible for the development of the milder type III mucolipidoses (gamma). All these diseases are characterized by impaired phosphorylation and transport of lysosomal enzymes, which is accompanied by severe growth retardation, skeletal abnormalities and early death of patients. Pathogenesis of mucolipidoses type IV, or sialolipidosis, associated with the simultaneous accumulation of phospholipids, sphingolipids, mucopolysaccharides and gangliosides, which occurs as a result of mutations in the MCOLN1 gene, encoding mucolipin 1, which forms a channel localized on the membranes of lysosomes and endosomes, involved in the regulation of lipid and protein transport. The article presents a description of clinical cases of mucolipidosis types II and IIIA. Preclinical trials have shown promise for enzyme replacement therapy, chaperone therapy, and gene therapy for the treatment of sialidosis and galactosialidosis. However, pathogenetic methods of therapy for mucolipidoses have not been described in clinical practice to date.